Monoaminergic system lesions increase post-sigh respiratory pattern disturbance during sleep in rats

Monoamines are important regulators of behavioral state and respiratory pattern, and the impact of monoaminergic control during sleep is of particular interest for the stability of breathing regulation. The aim of this study was to test the effects of systemically induced chemical lesions to noradrenergic and serotonergic efferent systems, on the expression of sleep-wake states, pontine wave activity, and sleep-related respiratory pattern and its variability. In chronically instrumented male adult Sprague-Dawley rats we lesioned noradrenergic terminal axonal branches by a single intraperitoneal dose of DSP-4 (N-(2-chloroethyl)-N-ethyl-2-brombenzilamine; 50 mg/kg, i.p.), and serotonergic axonal terminals by two intraperitoneal doses, 24 h apart, of PCA (p-chloroamphetamine; 6 mg/kg, i.p.). In each animal, we recorded sleep, pontine waves (P-waves) and breathing at baseline, following sham injection, and every week for 5 weeks following injection of either systemic neurotoxin. Distinct responses were observed to the two lesions. DSP-4 lesions were associated with a trend toward increased NREM sleep (p < 0.06), decreased wakefulness (p < 0.05) and increased respiratory tidal volume during NREM (p = 0.0002) and REM (p = 0.0001) sleep with respect to baseline. None of these effects, however, were observed during the first 14 days after injection. No significant changes were observed in the frequency of apneas or sighs, nor in the coupling between these two, at any time after DSP-4 injection. Conversely, selective serotonergic lesion by PCA produced no change in the baseline respiratory frequency or tidal volume during sleep or wakefulness, nor was the expression of Wake, NREM or REM sleep affected. Instead, PCA injection resulted in a sustained increase in the frequency and duration of post-sigh apneas (PS) during NREM sleep (p = 0.002). This reflected increased coupling between sighs and apneas, because neither the frequency nor the amplitude of spontaneous sighs was altered by PCA.

C-fiber activation exacerbates sleep-disordered breathing in rats

We reported previously that activation of vagal feedback by protoveratrines or serotonin exacerbates sleep apnea in rats, but each of these agents activates multiple afferent fiber types. To elucidate the specific impact of C-fiber activity on sleep apnea, the present study utilized capsaicin (CAP), which stimulates C-fibers via the CAP receptor. Nine adult Sprague-Dawley rats were instrumented for chronic polysomnography and recorded for 6 hours on four occasions. Prior to each recording, the animals received an intraperitoneal injection of either saline (control), or CAP 0.1, 1.0, or 10.0 mg/kg. Respiration was monitored by single-chamber plethysmography and apneas were scored as breaths longer than 2.5 seconds not preceded by a sigh. CAP increased apneas during non-rapid eye movement (NREM) sleep (p < 0.05 vs control) and reduced respiratory minute ventilation by about 15% in all behavioral states (waking, NREM, and REM sleep). We conclude that selective pharmacological activation of C-fibers produces a diathesis of sleep-disordered breathing specific to NREM sleep in rats.

Riluzole suppresses post-sigh, but not spontaneous apnoeas during sleep in rats

We conducted this experiment to determine the role of glutamate in the mechanism of sleep apnoeas by administering riluzole, a glutamate release inhibitor, to freely moving rats in which sleep-related apnoeas are physiological phenomena. Adult Sprague-Dawley rats were implanted with electrodes for electroencephalogram (EEG) and electromyogram (EMG) recording to monitor sleep and were placed inside a single-chamber plethysmograph to monitor respiration. Sleep and respiration were recorded for 6 h following intraperitoneal administration of 0.5, 5.0 and 10.0 mg kg(-1) riluzole. Riluzole dose-dependently suppressed post-sigh apnoeas during rapid eye movement (REM) sleep but had no effect on sleep-related spontaneous apnoeas. The drug (5.0 and 10.0 mg kg(-1)) also dose-dependently reduced wakefulness and increased sleep. It appears that glutamate, an excitatory neurotransmitter, plays a role in the genesis of the post-sigh apnoeas during REM sleep.

R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats

The effects of R-zacopride, a benzamide with potent 5-HT3 receptor antagonist and 5-HT4 receptor agonist properties, on spontaneous apneas were studied in 10 Sprague-Dawley rats by monitoring respiration and sleep for 6 h. R-zacopride (0.5, 1.0 and 10.0 mg/kg) suppressed spontaneous central apneas during non-rapid-eye-movement (NREM) sleep by 50% (P=.05 for 0.5 mg/kg, P=.02 for 1.0 mg/kg and P=.001 for 10.0 mg/kg dose vs. control), and during rapid-eye-movement (REM) sleep by 80% by all doses tested (P<.0007) for at least 2 h after intraperitoneal injection. We conclude that R-zacopride, over a 20-fold dose range, significantly reduces central apnea expression during NREM and REM sleep in the rat. The efficacy of this compound to suppress central apneas most probably arises from its antagonist actions at 5-HT3 receptors or from its mixed agonist/antagonist profile at 5-HT4/5-HT3 receptors.

Sleep-disordered respiration in phenotypically normotensive, genetically hypertensive rats

Increased prevalence of sleep-related breathing disorders has been reported in patients with essential hypertension and we have described disordered breathing in spontaneously hypertensive rats, an animal model of genetic hypertension. The mechanisms coupling hypertension to respiratory dysfunction during sleep remain, however, largely unknown. To determine if sleep-related respiratory disorder reflects cardiovascular derangement or, alternatively, represents an independent phenotype in hypertensive rats, we polygraphically recorded groups (n = 10) of genetically hypertensive, genetically normotensive, and phenotypically normotensive rats carrying a genetic background for hypertension. Apnea index was elevated more than 15-fold during NREM sleep in both animal groups carrying hypertension-related genes (p < 0.0001 for each) versus normotensive Wistar Kyoto rats. During REM sleep, a genetic background for hypertension was associated with an increased apnea index of at least 500% versus normotensive Wistar Kyoto rats (p < 0.0001 for each comparison). Still, overall mean respiratory rate, minute ventilation, and sleep architecture were equivalent among all animal groups. As expected, blood pressure and heart period were similar in both normotensive groups but elevated in the hypertensive animals. Persistent sleep-related breathing disorder despite effective cardiovascular normalization in the phenotypically normotensive but genetically hypertensive rats suggests that disordered breathing represents a genetically determined phenotype in these animals that is not secondary to the cardiovascular derangements. The model system described here may provide a powerful tool for investigation of the determinants of sleep-related breathing disorder.

Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat

Serotonin enhancing drugs, including L-tryptophan and, more recently, fluoxetine and paroxetine, have been tested as pharmacologic treatments for sleep apnea syndrome. Although some patients have demonstrated reduced apnea expression after treatment with these compounds, this improvement has been restricted to nonrapid eye movement (NREM) sleep, with some patients showing no improvement. This study reports the effects of mirtazapine, an antidepressant with 5-HT(1) agonist as well as 5-HT(2) and 5-HT(3) antagonist effects, on sleep and respiration in an established animal model of central apnea. We studied nine adult male Sprague-Dawley rats chronically instrumented for sleep staging. In random order on separate days, rats were recorded after intraperitoneal injection of: (1) saline, (2) 0.1 mg/kg +/- mirtazapine (labeled as Remeron), (3) 1 mg/kg mirtazapine, or (4) 5 mg/ kg mirtazapine. With respect to saline injections, mirtazapine at all three doses reduced apnea index during NREM sleep by more than 50% (p < 0.0001) and during REM sleep by 60% (p < 0.0001) for at least 6 h. In association with this apnea suppression normalized inspiratory minute ventilation increased during all wake/sleep states (p < 0.001 for each state). The duration of NREM sleep was unaffected by any dose of mirtazapine (p = 0.42), but NREM EEG delta power was increased by more than 30% at all doses (p = 0.04), indicating improved NREM sleep consolidation after mirtazapine injection. We conclude that mirtazapine, over a 50-fold dose range, significantly reduces central apnea expression during NREM and REM sleep in the rat. The efficacy of this compound to suppress apnea in all sleep stages most probably arises from its mixed agonist/antagonist profile at serotonin receptors. The implications of these findings for the management of sleep apnea syndrome must be verified by appropriate clinical trials.

Role of peripheral adenosine A(1) receptors in the regulation of sleep apneas in rats

The effects of administration of N(6)-p-sulfophenyladenosine (p-SPA), a peripheral adenosine A(1) receptor agonist, and 8-(p-sulfophenyl)theophylline (p-SPT), a peripheral adenosine A(1) receptor blocker, on spontaneous apneas were studied in 10 adult Sprague-Dawley rats by monitoring respiration, sleep, and blood pressure for 6 h. Intraperitoneal injection of p-SPA (1 mg/kg) to rats suppressed spontaneous central apneas during non-rapid eye movement sleep by 50% in comparison to control recordings (p = 0.03). This effect was blocked by pretreatment with an equimolar dose of p-SPT (0.67 mg/kg) indicating that p-SPA suppression of apneas was receptor mediated in the peripheral nervous system. Administration of p-SPA did not affect apnea expression in rapid eye movement sleep and had no effect on sleep or blood pressure at the dose tested. Administration of p-SPT (0.67, 6.7, and 30 mg/kg) to rats had no effect on apneas, sleep, or blood pressure. The lack of p-SPT effect on sleep apneas argues against a physiologic role for endogenous adenosine in the peripheral nervous system as a modulator of sleep apnea expression under baseline conditions.

Role of peripheral serotonin in the regulation of central sleep apneas in rats

STUDY OBJECTIVES

The aim of our study was to determine the effects of serotonin (5-HT), which does not penetrate the blood-brain barrier (BBB), and GR38032F, a 5-HT3 receptor antagonist that may cross the BBB, on spontaneous apneas in adult Sprague-Dawley rats.

MEASUREMENTS AND RESULTS

Rats were implanted with electrodes for EEG and electromyographic recording to monitor sleep, with a radiotelemetry transmitter for monitoring aortic BP and heart period (HP) and were placed inside a single chamber plethysmograph for monitoring respiration. Sleep, BP, HP, and respiration were monitored for 6 h following administration of drugs. Intraperitoneal injection of 5-HT (0.79 mg/kg) to rats increased spontaneous central apneas during rapid eye movement (REM) sleep by > 250% in comparison to control recording (p = 0.01). GR38032F (0.1 mg/kg), which produced no effect on apnea expression, completely blocked the 5-HT-induced increase in REM apneas. Administration of 5-HT did not affect apnea expression in non-REM sleep and had no effect on sleep or BP.

CONCLUSIONS

From these observations, we conclude that binding at 5-HT3 receptors in the peripheral nervous system promotes REM-related apnea genesis in rats. These findings further suggest that endogenous 5-HT, acting at least at peripheral 5-HT3 receptors, may play a baseline physiologic role in the expression of spontaneous central apneas in rats.

Serotonin 5-HT3-receptor antagonist GR 38032F suppresses sleep apneas in rats

The effects of administration of GR38032F, a 5-HT3 receptor antagonist, on spontaneous sleep apneas were studied in adult Sprague-Dawley rats by monitoring sleep, respiration and blood pressure for 6 hours. Intraperitoneal injection of GR38032F (1 mg/kg) suppressed spontaneous central apneas during non-rapid-eye-movement (NREM) and especially during rapid-eye-movement (REM) sleep. This effect was associated with increased respiratory drive but did not cause cardiovascular changes at the dose tested. The suppressive action of GR38032F on spontaneous sleep apneas is analogous to findings in anesthetized rats in which 5-HT and 2-methyl-5-HT provoked central apneas that were antagonized by GR38032 (Yoshioka et al, JPET 1992; 260:917-924). Our data implicate 5-HT3 receptor systems in determining sleep-related respiratory drive and apnea expression in rats, effects which are most probably mediated by vagal afferents.

Diazepam suppresses sleep apneas in rats

To test the respiratory effects of benzodiazepines in an established animal model of central apnea, we administered nonhypnotic and hypnotic doses of diazepam to nine adult male Sprague-Dawley rats chronically instrumented for sleep staging. In random order on separate days, rats were recorded following intraperitoneal injection of: (1) saline; (2) 0.05 mg/kg diazepam; or (3) 5 mg/kg diazepam. Normalized inspiratory minute ventilation increased significantly during wakefulness and non-rapid eye movement (non-REM) sleep following each dose of diazepam (p < 0.003 in each case) and following the highest dose during rapid eye movement (REM) sleep (p = 0.01). In accord with this respiratory stimulation, non-REM-related spontaneous and post-sigh apnea expression decreased following each dose of diazepam (p = 0.006 to 0.04), but REM-related apnea expression was unaffected despite significant respiratory stimulation. The durations of non-REM and REM sleep were unaffected by the low dose, but following 5 mg/kg of diazepam non-REM sleep was increased (p = 0.03) and REM sleep was decreased (p = 0.009). We conclude that both hypnotic and non-hypnotic doses of benzodiazepines may be associated with suppression of sleep-related central apnea. We further conclude that non-REM and REM-related apneas arise from at least partially distinct mechanisms.

Cardiopulmonary control in sleeping Sprague-Dawley rats treated with hydralazine

To test the hypothesis that hydralazine can suppress spontaneous sleep-related central apnea, respiratory pattern, blood pressure, and heart period were monitored in Sprague-Dawley rats. In random order and on separate days, rats were recorded after intraperitoneal injection of 1) saline or 2) 2 mg/kg hydralazine. Normalized minute ventilation (NVI) declined significantly with transitions from wake to non-rapid-eye-movement (NREM) sleep (-5.1%; P = 0.01) and rapid-eye-movement (REM) sleep (-4.2%; P = 0.022). Hydralazine stimulated respiration (NVI increased by 21%; P < 0.03) and eliminated the effect of state on NVI. Blood pressure decreased by 17% after hydralazine, and the correlation between fluctuations in mean blood pressure and NVI changed from strongly positive during control recordings to weakly negative after hydralazine (P < 0.0001 for each). Postsigh and spontaneous apneas were reduced during NREM and REM sleep after hydralazine (P < 0.05 for each). This suppression was strongly correlated with the reduction in blood pressure and with the degree of respiratory stimulation. We conclude that mild hydralazine-induced hypotension leads to respiratory stimulation and apnea suppression.

Adenosine A1 receptor agonist GR79236 suppresses apnea during all sleep stages in the rat

We tested the hypothesis that N-[(1S, trans)-2-hydroxycyclopentyl]adenosine (GR79236), a novel adenosine A1 receptor agonist, would suppress sleep-related apnea in the rat at doses not associated with hypotension or hypothermia. Nine adult Sprague-Dawley rats were instrumented for chronic recording of sleep by electroencephalographic and electromyographic monitoring. Respirations were measured by single chamber plethysmograph, and blood pressure and heart period were transduced by a telemetric implant. Each rat was polygraphically recorded for 6 hours on four occasions in random order, with recordings for an individual animal separated by at least 3 days. Fifteen minutes prior to each recording (0945 hours) each animal received a 1 ml/kg intraperitoneal bolus injection of one of four injectates: saline (control) or 0.03 mg/kg, 0.3 mg/kg, or 3 mg/kg of GR79236. The study was a repeated-measures balanced design such that each animal was recorded exactly once for each injectate. The rate of spontaneous apneas (pauses > 2.5 seconds) was significantly reduced during all sleep stages by all doses of GR79236. At the highest dose, apnea index was reduced by over 70% in both non-rapid eye movement (NREM) and rapid eye movement (REM) sleep. In contrast, GR79236 had no effect on sleep stage volumes or blood pressure at any dose tested. Heart rate and core temperature were reduced only at the highest dose (3 mg/kg). We conclude that the adenosine A1 receptor agonist GR79236 significantly suppresses apnea expression in all sleep stages at doses not associated with significant changes in sleep architecture, blood pressure, heart rate, or core temperature.

Protoveratrines A and B increase sleep apnea index in Sprague-Dawley rats

The action of protovertarines A and B, which stimulate carotid sinus baroreceptors and vagal sensory endings in the heart as well as pulmonary bed, were assessed on spontaneous and postsigh central sleep apneas in freely moving Sprague-Dawley rats. During the 6-h recording period, animals were simultaneously monitored for sleep by using electroencephalogram and electromyogram recordings, for respiration by single-chamber plethysmography, and for blood pressure and heart period by using radiotelemetry. After administration of 0.2, 0.5, or 1 mg/kg sc of protoveratrines, cardiopulmonary changes lasting at least 6 h were observed in all three behavioral states [heart period increased up to 23% in wakefulness, 21% in non-rapid-eye-movement (non-REM) sleep, and 20% in REM sleep; P < 0.005 for each]. At the same time, there was a substantial increase in the number of spontaneous (375% increase; P = 0.04) and postsigh (268% increase, P = 0.0002) apneas. Minute ventilation decreased by up to 24% in wakefulness, 25% in non-REM, and 35% in REM sleep (P < 0.05 for each). We conclude that pharmacological stimulation of baroreflexes promotes apnea expression in the sleeping rat.

Cardiopulmonary interactions following REM sleep deprivation in Sprague-Dawley rats

We characterized the effects of 48 h of rapid-eye-movement (REM) sleep deprivation on cardiovascular and respiratory variables and on sleep-related cardiopulmonary interactions in adult male Sprague-Dawley rats. Rats were instrumented for monitoring EEG, EMG, and aortic blood pressure. Respiratory rate and minute ventilation were measured by unrestrained single-chamber plethysmography. By using radiotelemetry to monitor blood pressure we clearly demonstrated progressive decreases in mean blood pressure with transitions from wakefulness to non-rapid-eye-movement and REM sleep which were unaffected by REM sleep deprivation. Mirror-image state-dependent increases in heart period suggest that baroreflexes were augmented during sleep with respect to wakefulness. REM sleep deprivation was also associated with lower blood pressure and longer heart period over all sleep/wake states, although this achieved statistical significance only during REM sleep and only during the first hour of recovery sleep. These cardiovascular changes coupled with the observed decreases in respiratory rate and minute ventilation suggest a further augmentation of baroreflexes following REM sleep deprivation.

Hypotension reduces sleep apneas in Zucker lean and Zucker obese rats

The effects of hypotension and obesity on spontaneous apnea (SA) and post-sigh sleep apnea (PSA) were studied in Zucker rats by monitoring blood pressure, respiration, and sleep state for 6 hours. Hypotension produced by intraperitoneal administration of hydralazine (2 mg/kg) was associated with reduced SA and PSA expression in nonrapid eye movement sleep in both lean and obese rats. In both animal groups, hypotension reduced rapid eye movement (REM) sleep by 50% but exerted no significant effect on REM-related expression of SA. Blood pressure lowering also correlated with increased respiratory rate and inspired minute ventilation during sleep, suggesting that the effects of hypotension on apnea expression may arrive via modulation of respiratory drive. These findings emphasize the interdependence of cardiorespiratory functions and may have implications regarding the mechanisms of central apnea in man.

Effects of inspired gas on sleep-related apnea in the rat

Central apneas have been reported to occur in the rat during all stages of sleep. Two types of apnea have been described: spontaneous and postsigh, which are immediately preceded by an augmented breath. We studied the effect of inspired gas on the number and type of apneas in nine adult male Sprague-Dawley rats that were surgically prepared with cortical electroencephalogram and nuchal electromyogram electrodes. In addition to the electroencephalogram and electromyogram, we recorded respiration by the barometric method by using a single-chamber plethysmograph. Each rat was recorded from 1000 until 1600 on 4 separate days by using different inspired gases: room air, 100% O2, 15% O2, and 5% CO2. We found that the sleep-related apnea index was significantly higher during 100% O2 compared with room air (P < 0.05) and was significantly lower during 15% O2 and 5% CO2 compared with room air (P < 0.05). Postsigh apneas occurred more frequently than did spontaneous apneas (P < 0.0001). The coupling between sighs and apneas was strengthened by hyperoxia and weakened by hypoxia and hypercapnia (P < 0.05 for each). We conclude that stimulation of chemoreceptors acts to oppose apnea in the rat.

Hydralazine reduces elevated sleep apnea index in spontaneously hypertensive (SHR) rats to equivalence with normotensive Wistar-Kyoto rats

The effects of lowering blood pressure (BP) by hydralazine (HY) (2 mg/kg) on spontaneous (SA) and post-sigh (PSA) sleep apneas have been studied in spontaneously hypertensive (SHR) rats by monitoring their respiration and sleep by the EEG for 6 hours. Normotensive Wistar-Kyoto (WKY) rats, from which the SHR rat strain was derived, were used as an appropriate control. The SHR rats had more SA (p < 0.02) and PSA (p < 0.0001) apneas/hour than WKY rats during nonrapid eye movement sleep and their mean BP was higher by 40 mm Hg (p < 0.0001) than WKY rats. Administration of HY to SHR rats equalized their BP with the arterial pressure of WKY rats and reduced the SA and the PSA apneas/hour to equivalence with WKY normotensive rats. These results demonstrate that even in the context of lifelong hypertension, acute normalization of BP significantly reduces sleep apneas in rats. They further suggest that improved management of BP may be clinical benefit to patients with apnea who have long-standing hypertension.

Sleep apnea in normal and REM sleep-deprived normotensive Wistar-Kyoto and spontaneously hypertensive (SHR) rats

The effects of hypertension and REM sleep deprivation on spontaneous and postsigh apneas have been studied in normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats by simultaneously monitoring their respiration and sleep by the EEG. The amount of REM and non-REM sleep in SHR rats was identical to WKY rats under control as well as REM sleep-deprived recording conditions. Hypertension was associated with an increase in postsigh apneas, as was evident by the increased postsigh apnea index in non-REM and total sleep in SHR rats when compared to normotensive WKY rats. In contrast, REM sleep deprivation suppressed the postsigh apnea expression both in non-REM and total sleep in SHR rats. The incidence of spontaneous apneas was increased by a combination of hypertension and REM sleep deprivation, as was shown in REM-deprived SHR rats, while each of these conditions alone had no effect on spontaneous apneas. These results suggest a role for hypertension in the postsigh apnea genesis and the existence of partially distinct mechanisms for the two types of apneas.

Effect of REM sleep deprivation on sleep apneas in rats

We studied the effects of 48 h of REM sleep deprivation on spontaneous and post-sigh central apneas in Sprague-Dawley rates by simultaneously monitoring sleep by the EEG and respiration for 6 h. During the recovery sleep following REM deprivation a decrease in post-sigh apneas occurred in total sleep. There was no change in spontaneous apneas. The results suggest the existence of partially distinct mechanisms for the two types of apneas.

p-SPA, a peripheral adenosine A1 analogue, reduces sleep apneas in rats

The actions of N6-p-sulfophenyladenosine (p-SPA), a novel peripherally selective adenosine A1 agonist, were assessed on spontaneous and postsigh central sleep apneas in freely moving, unanesthetized rats by simultaneously monitoring sleep and respiration. Intraperitoneal administration of 0.1, 0.3, and 1.0 mg/kg of the drug significantly decreased postsigh and spontaneous sleep apnea index (AI). This effect persisted throughout the 6-h recording period. Doses of 0.1 and 0.3 mg/kg did not affect sleep efficiency, whereas 1.0 mg/kg of p-SPA reduced it to 60% of baseline value.

Adenosine analogues modulate the incidence of sleep apneas in rats

The effects of adenosine A1 and A2 agonists on spontaneous central sleep apneas in rats have been examined by simultaneously monitoring sleep and respiration in freely moving unanesthetized animals. Intraperitoneal administration of 1.0 mg/kg of the A1 receptor agonist R(-)N6-L-(2-phenyl-isopropyl)adenosine (L-PIA) and 150 and 300 micrograms/kg of 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamido-adenosine hydrochloride (CGS 21680), a selective A2 agonist, decreased the apnea index (AI) during sleep. Within a sleep period, AI increased over time in both control and drug-treated animals. For both agonists, doses effective in reducing AI also significantly reduced sleep efficiency.

Effects of ethanol injection to the preoptic area on sleep and temperature in rats

Bilateral microinjection of ethanol to the preoptic area of rats causes a dose-dependent hypnotic effect at doses that do not affect brain temperature. Rats were polygraphically recorded for 6 h, and brain temperature was recorded every 10 min for 3 h. Administration of 0.047 mumol ethanol increased total sleep during the 3-6 h interval, while 0.24 and 0.47 mumol ethanol increased deep slow-wave sleep (SWS2) and total sleep during the 3-6- and 0-6-h intervals. The 0.24-mumol ethanol microinjections also increased REM sleep for the 0-6-h interval. No changes in sleep latencies were observed.

Role of adenosine in sleep and temperature regulation in the preoptic area of rats

We have examined the effects on sleep and brain temperature of bilateral microinjections of adenosine and adenosine analogs to the preoptic area (PO) of rats. Administration of adenosine (12.5 nmoles), a nonselective adenosine A1/A2 receptor agonist NECA (N-ethyl-carboxamido-adenosine, 1.0 nmole), and the selective adenosine A1 receptor agonist CPA (cyclopentyladenosine, 0.25, 0.5 nmoles) increased total sleep primarily through an enhancement in deep slow-wave sleep (SWS2), while adenosine also increased REM sleep. Administration of 12.5 nmoles adenosine and 0.25 nmoles CPA did not affect brain temperature, while 1.0 nmole NECA and 0.5 nmoles CPA caused a transient and prolonged hypothermia, respectively. Administration of the selective adenosine A2 receptor agonist CV-1808 (2-phenylaminoadenosine, 5, 10 nmoles) had no effect on sleep or brain temperature. The present results demonstrate a site for the central hypnotic action of adenosine, and a functional role for adenosine A1 receptors in the hypothalamus.

Chronic Ro 15-1788 treatment increases REM sleep in rats

Administration of Ro 15-1788, a benzodiazepine antagonist (3.6 mg/kg/day in drinking water for 14 days), increased total sleep and rapid eye movement (REM) sleep in rats. Standard six-hour EEG recording periods were obtained on day 0, 1, 3, 7, 10, 14, as well as 24 and 72 hours following withdrawal. Enhanced REM sleep reached significance on day 7 of continuous drug treatment and remained significantly increased on day 10 and 14, as well as at 24 and 72 hours following drug withdrawal. The present data show that chronic administration of Ro 15-1788 increases total sleep time due to increases in REM sleep. The actions of Ro 15-1788 presumably occur through either adenosinergic or cholinergic mechanisms.

The effect of soluflazine on sleep in rats

Soluflazine, a specific adenosine transport inhibitor, was intracerebroventricularly administered to rats in a dose range of 10, 25, and 50 nmoles. At a dose of 50 nmoles, soluflazine decreased waking and increased sleep during the first hour of EEG recording. Our previous work has shown that chronic intracerebroventricular administration of soluflazine to rats decreased radioligand binding to adenosine A1 and A2 receptors in specific brain regions. The present data show that administration of an adenosine transport inhibitor to rats produces a transient hypnotic effect presumably through increases in synaptic adenosine levels.

Radioligand binding to adenosine receptors and adenosine uptake sites in different brain regions of normal and narcoleptic dogs

The present study compares the characteristics of radioligand binding to adenosine receptors and adenosine uptake sites in 100- and 50-day-old normal and narcoleptic dogs. Binding to A1 receptors was quantified using a selective A1 agonist ([3H]N6-[(R)-1-methyl-2-phenylethyl] adenosine, [3H]R-PIA) and an antagonist ([3H]dipropyl-8-cyclopentyl-xanthine, [3H]CPX). Differences in the binding of [3H]R-PIA and that of [3H]5'-ethylcarboxamide adenosine ([3H]NECA), which binds to both A1 and A2 receptors with similar affinities, were used to quantify A2 receptors. Nucleoside transport sites were labeled with [3H]nitrobenzylthioinosine ([3H]NBTI), a potent inhibitor of nucleoside transport systems. The present study offered no evidence that either adenosine A1 receptors and adenosine uptake sites in the frontal cortex or adenosine A2 receptors in the putamen were altered in narcoleptic dogs. However, we found that adenosine A1 receptors in the dog exist in different affinity states and that the affinity state in which the receptor is found depends on the brain region examined. A characterization of these low- and high-affinity sites was performed and results indicated that these sites cannot be explained by a single interaction of the A1 receptor with a single G-protein population.

The effect of soluflazine on adenosine receptors in the rat brain

Soluflazine, a potent adenosine transport inhibitor, was intracerebroventricularly administered to rats via ALZET mini osmotic pumps (4nmole, 0.5 L/hr) for 14 days and the effect on adenosine receptors was determined in specific brain areas. Soluflazine decreased adenosine A1 radioligand binding in the hippocampus as measured by [3H]R-PIA, and lowered adenosine A2 binding sites in the striatum, as estimated by the "NECA minus R-PIA" assay. Previous work from our lab has shown the ability of diazepam and triazolam to decrease adenosine binding in the same brain areas. The data show that a specific adenosine transport inhibitor produces the same effect on adenosine receptors as benzodiazepines, and suggest a role for adenosine in the CNS effects of benzodiazepines.

A comparison of the effects of caffeine, 8-cyclopentyltheophylline, and alloxazine on sleep in rats. Possible roles of central nervous system adenosine receptors

The dose-response effects of administration of 8-cyclopentyltheophylline (CPT) (10, 20, and 40 mg/kg intraperitoneally [IP]) and alloxazine (ALX) (12.5, 25, and 50 mg/kg, IP) on sleep and wakefulness in rats were examined and compared to those of caffeine (12.5 mg/kg IP). Both CPT and ALX injected individually produced sleep suppression qualitatively similar to that produced by caffeine, but of a lower magnitude. However, when 20 mg/kg CPT and 50 mg/kg ALX were injected together, their sleep suppressant effect was of the same magnitude as that of 12.5 mg/kg caffeine. These results support the hypothesized involvement of adenosine receptor blockade in the effects of caffeine on sleep in rats. They further suggest that A1 adenosine receptor blockade may be more important than A2 receptor blockade, since behavioral effects of the selective in vitro A1 antagonist CPT were generally similar to those of nonselective in vitro adenosine receptor antagonists caffeine and ALX.

Effects of prolonged administration of triazolam on adenosine A1 and A2 receptors in the brain of rats

Continuous subcutaneous administration of triazolam, a benzodiazepine with short plasma half-life, for 10 days either decreased (31%, 2 mg/day) or increased (15%, 0.5 mg/day) radioligand binding to adenosine A2 receptors in the rat striatum. In a similar manner, we have shown previously that diazepam (5-10 mg/day), a benzodiazepine with a long plasma half-life attenuated radioligand binding to adenosine A2 receptors in the rat striatum by 45-25%.

Desensitization of adenosine A2 receptors in the striatum of the rat following chronic treatment with diazepam

Following prolonged treatment (7 days) with diazepam (10 mg/kg/day, using ALZET mini-osmotic pumps) in rats, the function of adenosine receptors was assessed in specific structures of the brain, using both agonist ligand binding and adenylate cyclase assays. Binding to A1 receptors was quantified using [3H]N6-[(R)-1-methyl-2-phenylethyl] adenosine, a selective ligand at A1 receptors. Differences in the binding of this ligand and that of [3H]5'-N-ethylcarboxamide adenosine, which binds to both A1 and A2 subtypes of receptors with similar affinities, were used to quantify A2 receptors. Treatment with diazepam failed to alter the binding of [3H]N6-[(R)-1-methyl-2-phenylethyl] adenosine in all areas of the brain studied. However, the binding of A2 receptors and A2 receptor-mediated stimulation of adenylate-cyclase were significantly attenuated in striatal membranes from diazepam-treated rats. Thus, the present study indicated that functional adenosine A2 receptors were desensitized after prolonged treatment with diazepam, since decreased agonist binding to A2 receptors paralleled an attenuation in the stimulation by adenosine of the activity of adenylate cyclase, an effect mediated by the A2 receptor. These results further indicate that the changes in adenosine A2 receptors correlated with significant short-lasting alterations in the sleep-wake cycle during the withdrawal of diazepam. The alterations in sleep-wakefulness did not correlate with the effect of diazepam on benzodiazepine receptors since no changes were observed in the binding of benzodiazepine receptors.

Effects of chronic administration of caffeine on adenosine A1 and A2 receptors in rat brain

Chronic administration of caffeine (75 mg/kg/day) to rats for 12 days increased [3H]R-PIA binding in the cerebral cortex and cerebellum and [3H]NECA binding to high affinity receptor sites in the striatum. The results indicate that both adenosine A1 and A2 receptor subtypes possess mechanisms of adaptation to chronic caffeine treatment. In addition, adenosine A1 receptor binding shows heterogenous neuroanatomical pattern indicating that the A1 response to caffeine treatment presents regional variation in the rat brain.

Chronic administration of diazepam downregulates adenosine receptors in the rat brain

Following chronic administration (10 or 20 days) of diazepam (5 mg/kg/day, subcutaneous pellets) or RO 15-1788 (5 mg/kg/day, intraperitoneally), adenosine and benzodiazepine receptors in different rat brain areas were assessed by radioligand binding studies using [3H]R-PIA for A1 receptors, [3H]NECA and [3H]R-PIA for A2 receptors and [3H]FNZ for benzodiazepine receptors. Chronic administration of diazepam for 10, but not for 20 days, decreased A2 receptors in the striatum by 46% (p less than 0.05) and A1 receptors in the hippocampus by 13% (p less than 0.05). Administration of diazepam for 10 days and 20 days failed to alter [3H]FNZ binding in all brain areas studied. However, 20 days of diazepam administration decreased the magnitude of GABA enhancement of [3H]FNZ binding in the cortex by 25% (p less than 0.05). In contrast, chronic administration of RO 15-1788 failed to alter [3H]R-PIA, [3H]NECA and [3H]FNZ binding in all brain areas. These results suggest that adenosine receptors may play a role in the CNS actions of benzodiazepines.

Low-frequency oscillations of cortical oxidative metabolism in waking and sleep

To study the changes in cortical oxidative metabolism and blood volume during behavioral state transitions, we employed reflectance spectrophotometry of the cortical cytochrome c oxidase (cyt aa3) redox state and blood volume in unanesthetized cats implanted with bilateral cortical windows and EEG electrodes. Continuous oscillations in the redox state and blood volume (approximately 9/min) were observed during waking and sleep. These primarily metabolic oscillations of relatively high amplitude were usually synchronous in homotopic cortical areas, and persisted during barbiturate-induced electrocortical silence. Their mean amplitude and frequency did not vary across different behavioral/EEG states, although the mean levels of cyt aa3 oxidation and blood volume during rapid eye movement (REM) sleep significantly exceeded those during waking and slow-wave sleep. These data suggest the existence of a spontaneously oscillating metabolic phenomenon in cortex that is not directly related to neuroelectric activity. A superimposed increase in cortical oxidative metabolism and blood volume occurs during REM sleep. Experimental data concerning cerebral metabolism and blood flow that are obtained by clinical methods that employ relatively long sample acquisition times should therefore be interpreted with caution.

Desensitization of adenosine and dopamine receptors in rat brain after treatment with adenosine analogs

Maximally tolerated doses of N6-[(R)-1-methyl-2-phenylethyl] adenosine (0.50 nmol/hr/2 wk), 5'-N-ethylcarboxamide adenosine (NECA, 0.04 nmol/hr/2 wk) or deoxycoformycin (5 nmol/hr/1 wk) were administered i.c.v. to rats using mini-osmotic pumps. Adenosine receptor function was subsequently assayed using both ligand binding and adenylate cyclase assays. Binding to A1 receptors was quantitated using [3H]N6-[(R)-1-methyl-2-phenylethyl]adenosine, a selective agonist ligand at A1 receptors. Differences in the binding of this ligand and that of [3H]NECA, which binds to A1 and A2 receptors with similar affinities, were used to quantitate A2 receptors. None of the treatments affected A1 receptor function as assessed by both ligand binding and adenylate cyclase assays. A2 receptor binding and A2 receptor-mediated stimulation of adenylate cyclase were blunted in striatal membranes from NECA- and deoxycoformycin-treated rats but unaffected in striatal membranes from N6-[(R]-1-methyl-2-phenylethyl]adenosine-treated rats. All three pretreatments attenuated D1 dopamine receptor-mediated stimulation of adenylate cyclase in striatal membranes. These results suggest that 1) the A2 adenosine receptor system is susceptible to desensitization and 2) different mechanisms are involved in the NECA- and deoxycoformycin-induced desensitization of A2 adenosine receptor and D1 dopamine receptor systems. It is suggested that the D1 dopamine receptor desensitization is, in fact, due to the tonic stimulation of adenosine A1 receptors.

Dose-response effects of 8-cyclopropyltheophylline on sleep and wakefulness in rats

The dose-response effects of the substituted xanthine 8-cyclopropyltheophylline (CPRT) on sleep and wakefulness (W) after intraperitoneal administration to rats were examined by means of simultaneous electroencephalographic (EEG) and electromyographic (EMG) recordings. Doses of 20 and 40 mg/kg CPRT increased W and decreased slow wave sleep (SWS) in rats, indicating CNS stimulant effects. The greatest CNS stimulation was produced by the lowest (20 mg/kg) dose of CPRT examined, which also increased the latency to SWS. In addition, the 20 mg/kg dose of CPRT also significantly decreased the amount of total sleep (TS), as compared to the vehicle group, during all time periods examined. In contrast, the 80 mg/kg dose of CPRT decreased W and increased both SWS and TS. However, this apparent hypnotic effect of the 80 mg/kg CPRT may be due to toxicity, since 80% of rats treated with this dose of the drug died within 48 h of injection.

An inexpensive sleep-wake state analyzer for the rat

Manual classification of sleep stages is a tedious and time consuming task. We describe an inexpensive system for sleep-wake state classification for as many as eight rats at a time. It is based on determining threshold values for each parameter of each rat, then finding the natural transitions from one sleep state to another and finally classifying these states utilizing the cortical EEG and EMG signals.

A simplified method for monitoring the cytochrome aa3 redox state in bilateral cortical areas of unanesthetized cats

We describe a versatile optical system that enables the simultaneous monitoring of the redox state of cytochrome c oxidase (cytochrome aa3) in two homologous cortical areas under chronically implanted windows in cats. A single light source, broad bandpass primary filters, light-conducting rods, and narrow-bandpass interference detecting filters are employed. We observed reproducible responses of the cytochrome redox state and blood volume to carotid occlusion and terminal anoxia during anesthesia, and to graded doses of pentobarbital in awake animals.

The dose-response effects of caffeine on sleep in rats

Caffeine at doses of 0.125, 1.25, 12.5 and 25 mg/kg was administered to rats and the subsequent effects on the sleep-wake cycle were measured. The 12.5 and 25 mg/kg doses of caffeine increased wakefulness, and decreased slow wave sleep-1 (SWS1), SWS2, rapid eye movement (REM) sleep and total sleep time (P less than or equal to 0.05). The 0.125 and 1.25 mg/kg doses of caffeine increased SWS1 at the expense of SWS2 (P less than or equal to 0.05), and did not affect total sleep time in any time period measured. Adenosine or adenosine agonists have been shown to increase SWS2 at the expense of waking or SWS1 with an increase in total sleep time. The effects of caffeine on sleep reported in this study suggest that caffeine administration not only antagonizes the effects of adenosine at the receptor level, but also at the behavioral level.

REM sleep deprivation up-regulates adenosine A1 receptors

Adenosine receptor binding was determined in the brains of rats deprived of rapid eye movement (REM) sleep for 48 and 96 h using [3H]L-phenylisopropyladenosine. Adenosine A1 receptors (Bmax) were significantly increased in the cortex and corpus striatum, and this increase was sleep-specific. Endogenous adenosine was assayed in microwave-fixed brain tissue and no significant changes were found in REM-deprived rats.

Lack of effect of 1-methylisoguanosine on sleep in rats

The dose-response effects of intracerebroventricular (i.c.v.) administration of 1-methylisoguanosine (MIG) on sleep in rats were examined. Not even the largest dose (100 nmol/rat) of 1-methylisoguanosine produced significant hypnotic effects, whereas doses of 10 and 100 nmol/rat suppressed rapid eye movement sleep in rats. The only statistically significant effect of 1-methylisoguanosine on sleep latencies was an increase in the latency of S2 after intracerebroventricular administration of 100 nmol/rat of the drug. These effects of 1-methylisoguanosine on sleep were unlike those of both adenosine and the benzodiazepines, suggesting that, contrary to earlier speculations, 1-methylisoguanosine does not interact with central adenosine or benzodiazepine receptors.

Prenatal exposure to diazepam results in enduring reductions in brain receptors and deep slow wave sleep

After prenatal exposure to diazepam (Valium), mature rats at 4 months of age displayed slow wave sleep (SWS) electroencephalographic patterns indicating impaired synchronization and SWS mechanisms. These animals spent a much greater portion of their SWS in the lighter SWS I, as compared to the control group which showed a predominance of the deeper SWS II. At one year of age, the diazepam-exposed rats had much fewer diazepam-specific binding sites in the thalamus than the vehicle-exposed controls. These results provide first evidence for a physiological role for benzodiazepine receptors by showing that prenatal exposure to diazepam has an enduring and detrimental effect on their ontogenesis and sleep mechanisms.

A comparison of the dose response effects of pyrimidine ribonucleosides and adenosine on sleep in rats

The dose-response effects of intracerebroventricular (ICV) infusion of the pyrimidine ribonucleosides cytidine and uridine and the purine ribonucleoside adenosine on sleep and wakefulness (W) in rats were examined and compared. All three drugs were administered at doses of 1,10, and 100 nmol in volumes of 5 microliter, with control animals receiving equivolumetric infusions of 0.9% saline. Treatment with 1 nmol cytidine significantly increased W and decreased both deep slow wave sleep (S2) and total sleep (TS) during both the 3-6 and 0-6 h recording periods. In addition, this dose of cytidine significantly increased light slow wave sleep (S1) during the first 3 h of recording. The 10 nmol dose of cytidine increased W and decreased TS during the 0-6 h recording. ICV administration of uridine produced no significant changes in sleep and W at any dose during any of the recording periods examined. In contrast, adenosine exhibited significant hypnotic effects at all doses examined. All three doses of adenosine significantly reduced W and increased TS during both the 0-3 and 0-6 h recording periods. The 1 and 100 nmol doses of adenosine also significantly increased S2 during both the 0-3 and 0-6 h periods. In addition, the 100 nmol dose of adenosine significantly decreased W and increased both S2 and TS during the second 3 h of recording. Both the 1 and 100 nmol doses of adenosine also significantly reduced the latencies to the onset of rapid eye movement (REM) sleep.(ABSTRACT TRUNCATED AT 250 WORDS)

Diazepam and midazolam increase light slow-wave sleep (SWS1) and decrease wakefulness in rats

Rats implanted with electrodes for polygraphic recordings were injected with diazepam (5 mg/kg, i.p.) or midazolam (10 mg/kg, i.p.) and recorded for 6 h during the 8 h of darkness of a 16 h light/8 h dark cycle. The results show that administration of diazepam reduced SWS1 latency by 92%, and increased SWS1 and total sleep by 255% and 59%, respectively, in comparison to control. Administration of midazolam increased SWS1 by 158% and total sleep by 57% when compared to control. These findings correlate well with the effects of benzodiazepines on sleep stage 2 in humans and indicate that benzodiazepine hypnotics increase only the behaviorally lighter stage of SWS in rats as well as in human subjects.

Circadian variation of [3H]N6-(L-phenylisopropyl)adenosine binding in rat brain

Since considerable recent experimental evidence suggests a role for the purine nucleoside adenosine in the regulation of mammalian sleep, circadian variations of adenosine receptor binding were examined in whole rat brain using [3H]N6-(L-phenylisopropyl)adenosine ([3H]L-PIA). These results demonstrate a significant circadian variation in the number of [3H]L-PIA binding sites (Bmax) with a maximum 3 h after the beginning of the dark phase of a 12 h light/12 h dark cycle, and a minimum 8 h later (P less than 0.025). The dissociation constant (Kd) of [3H]L-PIA at adenosine receptors did not exhibit any statistically significant circadian variation. These data indicate a daily rhythm in the number of adenosine receptors without a change in Kd and may support the hypothesized involvement of adenosine in the regulation of sleep in rats.

[3H]N6-(L-Phenylisopropyl) adenosine binding in brains from young and old rats

The binding of [3H]N6-(L-Phenylisopropyl) adenosine (L-PIA) to membrane preparations of whole brains from normal male Sprague-Dawley rats 12 and 84 weeks of age, respectively, was examined. Two populations of binding sites, probably corresponding to A1 and A2 adenosine receptors, were detected in both young and old rats. No statistically significant differences between young and old rats were detected but both the numbers of binding sites (Bmax) and dissociation constants (KD) for both high and low affinity binding sites were greater in 84 week old rats. These results were compared to earlier studies of adenosine receptors and related to previously reported changes in sleep with aging in rats.

Adenosine analogs and sleep in rats

The effects of N6-L-(phenylisopropyl)adenosine, cyclohexyladenosine and adenosine-5'-N-ethylcarboxamide on sleep were examined in rats. These effects consist of 1) increased slow-wave sleep2 from 6.6 to 45.7%, in all doses used for cyclohexyladenosine and adenosine-5'-N-ethylcarboxamide and for 0.1 and 0.3 mumol/kg of N6-L-(phenylisopropyl)adenosine and 2) increased values for rapid-eye-movement-sleep, amounting to 56.2 and 51.6% for 0.1 mumol/kg of cyclohexyl-adenosine and 0.3 mumol/kg of N6-L-(phenylisopropyl)adenosine, respectively. Slow-wave sleep1 decreased but values for wakefulness and total sleep were unchanged for 0.03, 0.1 and 0.3-mumol/kg doses of the drugs. Only 0.9-mumol/kg dose of cyclohexyladenosine and N6-L-(phenylisopropyl)adenosine increased wakefulness and decreased total sleep, whereas the same dose of adenosine-5'-N-ethylcarboxamide increased total sleep during the 0- to 3-hr time interval. All three agents reduced rapid-eye-movement sleep at the 0.9-mumol/kg dose. The results indicate that the effect on sleep of all three adenosine analogs was obtained with nanomolar doses of the drugs and that it diminished or disappeared when the drug dose reached micromolar range (0.9 mumol/kg). It appears, therefore, that activation of A1 rather than A2 receptors contributed to the sleep effects of the drugs because adenosine and adenosine analogs activate A1 receptors in nanomolar quantities whereas activation of A2 receptors requires micromolar concentration of these compounds.(ABSTRACT TRUNCATED AT 250 WORDS)

Muramyl dipeptide does not induce slow-wave sleep or fever in rats

The synthetic muramyl dipeptide, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP), is reported to increase slow-wave sleep and body temperature in cats, rabbits, and squirrel monkeys. The present study examined the ability of MDP to induce sleep and fever in rats. MDP was administered IP at 50, 250 and 500 micrograms/kg. Sleep and body temperature were monitored for 12 hr. MDP failed to affect the duration of wakefulness, S1, S2, or total (S1 + S2) slow-wave sleep. There was also no change in the latency to the first episode of S2 sleep. In contrast, rapid-eye-movement (REM) sleep was significantly suppressed for the first 6 hr after 250 and 500 microgram/kg doses of MDP. There was, however, a rebound increase in REM sleep after the initial period of suppression which resulted in no overall change in the amount of REM sleep. Body temperature was unaffected by MDP. Thus, we conclude that MDP has neither sleep-promoting nor pyrogenic actions in the rat when administered systemically at doses reported to be effective in several other species.